Alcon's Clareon Panoptix Pro IOL enhances cataract surgery with advanced light utilization and low visual disturbance.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ...

The trial will evaluate the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in ...

PulseSight Technologies recently announced the successful dosing of the first patient in the phase I clinical trial ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Healthcare professionals must stop supplying the affected batch, quarantine stock, and return it to suppliers.

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

EYP-1901 shows promising results in reducing treatment burden for diabetic macular edema, offering sustained improvements in ...

In honor of Ophthalmology Times’ 50th anniversary, anterior segment surgeons attending ASCRS 2025 weigh in on the innovations ...

Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

LumiThera’s PBM is the only device that has demonstrated meaningful vision improvement compared to baseline for people living ...